Tracey G Simon1, Maria Esther Perez Trejo2, Robyn McClelland2, Ryan Bradley3, Michael J Blaha4, Irfan Zeb5, Kathleen E Corey1, Matthew J Budoff6, Raymond T Chung7. 1. Liver Center, Gastrointestinal Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. 2. Department of Biostatistics, University of Washington, Seattle, WA, United States. 3. Division of Preventive Medicine, University of California, San Diego, La Jolla, CA, United States. 4. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, United States. 5. Department of Cardiology, Mount Sinai St. Luke's Roosevelt Hospital (Bronx-Lebanon Hospital Center), United States. 6. Los Angeles Biomedical Research Institute, Division of Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, United States. 7. Liver Center, Gastrointestinal Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. Electronic address: rtchung@partners.org.
Abstract
BACKGROUND: Biomarkers to predict the presence and severity of subclinical cardiovascular disease (CVD) in nonalcoholic fatty liver disease (NAFLD) are lacking. METHODS: 3876 participants from the Multi-Ethnic Study of Atherosclerosis (MESA), without known chronic liver disease underwent baseline non-contrast cardiac CT, with NAFLD defined by validated liver:spleen ratio (L:S) < 1.0, and subclinical CVD defined by coronary artery calcium (CAC) score > 0. Randomly-selected subgroups underwent detailed inflammatory marker testing, including LpPLA2 mass (N = 2951), activity (N = 3020), high-sensitivity C-reactive protein (hsCRP; N = 3849), and interleukin-6 (IL-6; N = 3764). Among those with NAFLD, we estimated the prevalence of CAC > 0 and CAC > 100 for each SD biomarker increase, using multivariable log-binomial regression models adjusted for cardiometabolic risk factors. RESULTS: Seventeen percent (N = 668) of participants met the criteria for NAFLD. NAFLD participants were younger (mean age 61 ± 10 vs. 63 ± 10 years, p < .0001) but more likely to have an elevated BMI (mean 31.1 ± 5.5 vs. 28.0 ± 5.2 kg/m2, p < .0001), diabetes (22% vs. 11%, p < .0001), and increased inflammatory biomarkers, including LpPLA2 activity, hsCRP and IL-6 (all p < .0001). Among NAFLD participants, IL-6 was the only biomarker independently associated with prevalent CAC > 0 (PR = 1.06 [1.00-1.11]), or CAC > 100 (PR = 1.09 [1.02-1.17]). In contrast, circulating LpPLA2 mass/activity and hsCRP were not associated with either the prevalence or severity of subclinical CVD (all p > .05). CONCLUSION: In a large, multi-ethnic population with NAFLD, IL-6 is independently associated with the prevalence and severity of subclinical atherosclerosis. Further research into the longitudinal effects of NAFLD on progressive CVD will determine whether IL-6 is a marker or mediator of NAFLD-related atherosclerosis.
BACKGROUND: Biomarkers to predict the presence and severity of subclinical cardiovascular disease (CVD) in nonalcoholic fatty liver disease (NAFLD) are lacking. METHODS: 3876 participants from the Multi-Ethnic Study of Atherosclerosis (MESA), without known chronic liver disease underwent baseline non-contrast cardiac CT, with NAFLD defined by validated liver:spleen ratio (L:S) < 1.0, and subclinical CVD defined by coronary artery calcium (CAC) score > 0. Randomly-selected subgroups underwent detailed inflammatory marker testing, including LpPLA2 mass (N = 2951), activity (N = 3020), high-sensitivity C-reactive protein (hsCRP; N = 3849), and interleukin-6 (IL-6; N = 3764). Among those with NAFLD, we estimated the prevalence of CAC > 0 and CAC > 100 for each SD biomarker increase, using multivariable log-binomial regression models adjusted for cardiometabolic risk factors. RESULTS: Seventeen percent (N = 668) of participants met the criteria for NAFLD. NAFLD participants were younger (mean age 61 ± 10 vs. 63 ± 10 years, p < .0001) but more likely to have an elevated BMI (mean 31.1 ± 5.5 vs. 28.0 ± 5.2 kg/m2, p < .0001), diabetes (22% vs. 11%, p < .0001), and increased inflammatory biomarkers, including LpPLA2 activity, hsCRP and IL-6 (all p < .0001). Among NAFLD participants, IL-6 was the only biomarker independently associated with prevalent CAC > 0 (PR = 1.06 [1.00-1.11]), or CAC > 100 (PR = 1.09 [1.02-1.17]). In contrast, circulating LpPLA2 mass/activity and hsCRP were not associated with either the prevalence or severity of subclinical CVD (all p > .05). CONCLUSION: In a large, multi-ethnic population with NAFLD, IL-6 is independently associated with the prevalence and severity of subclinical atherosclerosis. Further research into the longitudinal effects of NAFLD on progressive CVD will determine whether IL-6 is a marker or mediator of NAFLD-related atherosclerosis.
Authors: J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano Journal: Radiology Date: 2005-01 Impact factor: 11.105
Authors: J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: Rajesh Tota-Maharaj; Michael J Blaha; Irfan Zeb; Ronit Katz; Ron Blankstein; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir Journal: Mayo Clin Proc Date: 2014-03-07 Impact factor: 7.616
Authors: Emil M DeGoma; Benjamin French; Richard L Dunbar; Matthew A Allison; Emile R Mohler; Matthew J Budoff Journal: Atherosclerosis Date: 2012-07-20 Impact factor: 5.162
Authors: Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark Journal: Am J Epidemiol Date: 2013-05-23 Impact factor: 4.897
Authors: Daniel I Swerdlow; Michael V Holmes; Karoline B Kuchenbaecker; Jorgen E L Engmann; Tina Shah; Reecha Sofat; Yiran Guo; Christina Chung; Anne Peasey; Roman Pfister; Simon P Mooijaart; Helen A Ireland; Maarten Leusink; Claudia Langenberg; Ka Wah Li; Jutta Palmen; Philip Howard; Jackie A Cooper; Fotios Drenos; John Hardy; Michael A Nalls; Yun Rose Li; Gordon Lowe; Marlene Stewart; Suzette J Bielinski; Julian Peto; Nicholas J Timpson; John Gallacher; Malcolm Dunlop; Richard Houlston; Ian Tomlinson; Ioanna Tzoulaki; Jian'an Luan; Jolanda M A Boer; Nita G Forouhi; N Charlotte Onland-Moret; Yvonne T van der Schouw; Renate B Schnabel; Jaroslav A Hubacek; Ruzena Kubinova; Migle Baceviciene; Abdonas Tamosiunas; Andrzej Pajak; Roman Topor-Madry; Sofia Malyutina; Damiano Baldassarre; Bengt Sennblad; Elena Tremoli; Ulf de Faire; Luigi Ferrucci; Stefania Bandenelli; Toshiko Tanaka; James F Meschia; Andrew Singleton; Gerjan Navis; Irene Mateo Leach; Stephan J L Bakker; Ron T Gansevoort; Ian Ford; Stephen E Epstein; Mary Susan Burnett; Joe M Devaney; J Wouter Jukema; Rudi G J Westendorp; Gert Jan de Borst; Yolanda van der Graaf; Pim A de Jong; Anke-Hilse Mailand-van der Zee; Olaf H Klungel; Anthonius de Boer; Pieter A Doevendans; Jeffrey W Stephens; Charles B Eaton; Jennifer G Robinson; JoAnn E Manson; F Gerry Fowkes; Timonthy M Frayling; Jackie F Price; Peter H Whincup; Richard W Morris; Debbie A Lawlor; George Davey Smith; Yoav Ben-Shlomo; Susan Redline; Leslie A Lange; Meena Kumari; Nick J Wareham; W M Monique Verschuren; Emelia J Benjamin; John C Whittaker; Anders Hamsten; Frank Dudbridge; J A Chris Delaney; Andrew Wong; Diana Kuh; Rebecca Hardy; Berta Almoguera Castillo; John J Connolly; Pim van der Harst; Eric J Brunner; Michael G Marmot; Christina L Wassel; Steve E Humphries; Philippa J Talmud; Mika Kivimaki; Folkert W Asselbergs; Mikhail Voevoda; Martin Bobak; Hynek Pikhart; James G Wilson; Hakon Hakonarson; Alex P Reiner; Brendan J Keating; Naveed Sattar; Aroon D Hingorani; Juan Pablo Casas Journal: Lancet Date: 2012-03-14 Impact factor: 79.321